BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Merck & Co., Inc. (MRK) Unit Sues Glenmark Pharmaceuticals for Infringing Patent on Diabetes Drugs


4/3/2013 7:54:56 AM

US-based MSD Pharma, the third-largest pharma company in the world by revenues, has asked the Delhi High Court to bar Mumbai-based Glenmark from selling two popular anti-diabetic drugs, triggering yet another legal battle between an Indian generic company and a member of Big Pharma. MSD's move comes a week after Glenmark Pharma launched generic versions of a range of anti-diabetes products sold by the US company under the brand names Januvia and Janumet. Glenmark has branded its medicines Zita and Zita Met and aims to grab a share of the 3,000-crore Indian anti-diabetic market. MSD's drug costs 40 per tablet. Glenmark officials, who did not wish to go on record, said it has priced its product at a 20% discount to the innovator's version.



   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->